Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model
- PMID: 9060650
- PMCID: PMC191419
- DOI: 10.1128/JVI.71.4.2921-2927.1997
Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model
Abstract
Antibody-dependent enhancement of flavivirus infection, which except for dengue virus is without clear proof in vivo, is still under debate. Recently, postexposure immunoglobulin prophylaxis against tick-borne encephalitis virus, a flavivirus, was claimed to possibly have worsened the outcome of infection due to antibody-dependent enhancement. In the present study, antibody-dependent enhancement and pre- or postexposure protection by passive administration of tick-borne encephalitis virus immunoglobulin were evaluated in a mouse model. Preexposure treatment with homologous murine or heterologous human immunoglobulin provided complete protection against lethal challenge with tick-borne encephalitis virus. For postexposure treatment with antibody, the degree of protection correlated with the amount of immunoglobulin administered and was inversely related to the time interval between infection and treatment. Indications of enhancement of infection would have been increased lethality or reduced mean survival time, but neither was observed under the conditions used in our experiments despite the broad range of immunoglobulin and virus challenge doses applied. In contrast to these in vivo results, antibody-dependent enhancement of tick-borne encephalitis virus infection of murine peritoneal macrophages was readily demonstrable in vitro. Thus, antibody-dependent enhancement of viral infection in vitro does not necessarily predict enhancement in vivo.
Similar articles
-
Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.J Virol. 2001 Sep;75(17):8259-67. doi: 10.1128/jvi.75.17.8259-8267.2001. J Virol. 2001. PMID: 11483771 Free PMC article.
-
Stable and Highly Immunogenic MicroRNA-Targeted Single-Dose Live Attenuated Vaccine Candidate against Tick-Borne Encephalitis Constructed Using Genetic Backbone of Langat Virus.mBio. 2019 Apr 23;10(2):e02904-18. doi: 10.1128/mBio.02904-18. mBio. 2019. PMID: 31015334 Free PMC article.
-
Broadly neutralizing monoclonal antibodies protect against multiple tick-borne flaviviruses.J Exp Med. 2021 May 3;218(5):e20210174. doi: 10.1084/jem.20210174. J Exp Med. 2021. PMID: 33831142 Free PMC article.
-
[Efficiency of use of immunoglobulin preparations for the postexposure prevention of tick-borne encephalitis in Russia (a review of semi-centennial experience)].Med Parazitol (Mosk). 2010 Jan-Mar;(1):53-9. Med Parazitol (Mosk). 2010. PMID: 20361640 Review. Russian.
-
[Metaanalysis of the efficiency of use of immunoglobulin preparations for the postexposure prophylaxis against tick-borne encephalitis in Russia].Med Parazitol (Mosk). 2010 Jul-Sep;(3):58-63. Med Parazitol (Mosk). 2010. PMID: 20873186 Review. Russian. No abstract available.
Cited by
-
Subversion of early innate antiviral responses during antibody-dependent enhancement of Dengue virus infection induces severe disease in immunocompetent mice.Med Microbiol Immunol. 2014 Aug;203(4):231-50. doi: 10.1007/s00430-014-0334-5. Epub 2014 Apr 11. Med Microbiol Immunol. 2014. PMID: 24723052
-
Current trends in West Nile virus vaccine development.Expert Rev Vaccines. 2014 May;13(5):589-608. doi: 10.1586/14760584.2014.906309. Epub 2014 Apr 1. Expert Rev Vaccines. 2014. PMID: 24689659 Free PMC article. Review.
-
The regulation and maturation of antiviral immune responses.Adv Virus Res. 2004;63:181-238. doi: 10.1016/S0065-3527(04)63003-X. Adv Virus Res. 2004. PMID: 15530562 Free PMC article. Review. No abstract available.
-
Tick-borne encephalopathies : epidemiology, diagnosis, treatment and prevention.CNS Drugs. 2005;19(12):1009-32. doi: 10.2165/00023210-200519120-00004. CNS Drugs. 2005. PMID: 16332143 Review.
-
The antiviral activity of antibodies in vitro and in vivo.Adv Immunol. 2001;77:195-262. doi: 10.1016/s0065-2776(01)77018-6. Adv Immunol. 2001. PMID: 11293117 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical